US4618627A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Catechol derivatives and pharmaceutical compositions thereof for inhibiting anaphylaxis (SRS-A)
Assignee: Astellas Pharma Inc
•
Filing: 1984-05-11
•
Granted: 1986-10-21
•
Expires: 2004-05-11
Abstract
Abstract A catechol derivative represented by the formula <IMAGE> The compounds of this invention are useful for the prophylaxis and treatment for various allergic diseases, ischemic heart diseases and inflammations caused by slow reacting substance of anaphylaxis (SRS-A), since the compounds inhibit very potently the formation and release of SRS-A.
Inventors
- 👤 Kiyoshi Murase
- 👤 Toshiyasu Mase
- 👤 Hideki Arima
- 👤 Kenichi Tomioka
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 22:45
CPC Classifications
C; C07; C07C; C07C59/00; C07C59/40; C07C59/58; C07C59/64; A; A61; A61P; A61P1/00; A61P1/04; C07C37/00; C07C37/001; C07C37/002; C07C37/01; C07C37/055; C07C37/62; C07C39/00; C07C39/02; C07C39/11; C07C41/00; C07C41/01; C07C41/18; C07C41/26; C07C43/00; C07C43/02; C07C43/20; C07C43/23; C07C45/00; C07C45/27; C07C45/29; C07C45/292; C07C45/56; C07C45/57; C07C45/59; C07C45/61; C07C45/67; C07C45/673; C07C45/68; C07C45/70; C07C45/71; C07C45/72; C07C49/00; C07C49/20; C07C49/24; C07C49/245; C07C49/248; C07C49/255; C07C49/76; C07C49/84; C07C59/42; C07C59/52; C07F; C07F9/00; C07F9/02; C07F9/28; C07F9/38; C07F9/40; C07F9/4003; C07F9/4006; C07C2601/00; C07C2601/12; C07C2601/14
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
117 words
A catechol derivative represented by the formula ##STR123## wherein R 1 represents a hydrogen atom; R 2 represents a hydrogen atom or a halogen atom; X represents a straight chain or branched alkylene group having 1 to 15 carbon atoms or a vinylene group; Y represents a carbonyl group or a group represented by ##STR124## (wherein R 3 and R 4 , which may be the same or different, each represents a hydrogen atom or a lower alkyl group) and Z represents a hydrogen atom, a straight chain or branched alkyl group having 1 to 15 carbon atoms or a cycloalkyl group; the sum of the carbon atoms of said X and Z being at least 7.
Claim 2
Dependent Claim
117 words
A catechol derivative represented by the formula ##STR123## wherein R 1 represents a hydrogen atom; R 2 represents a hydrogen atom or a halogen atom; X represents a straight chain or branched alkylene group having 1 to 15 carbon atoms or a vinylene group; Y represents a carbonyl group or a group represented by ##STR124## (wherein R 3 and R 4 , which may be the same or different, each represents a hydrogen atom or a lower alkyl group) and Z represents a hydrogen atom, a straight chain or branched alkyl group having 1 to 15 carbon atoms or a cycloalkyl group; the sum of the carbon atoms of said X and Z being at least 7.
Claim 3
Dependent Claim
12 words
The compound as claimed in claim 1 wherein the compound is 11-(3,4-dihydroxyphenyl)-1-undecanol.
Claim 4
Dependent Claim
12 words
The compound as claimed in claim 1 wherein the compound is 10-(3.4-dihydroxyphenyl)-1-decanol.
Claim 5
Dependent Claim
12 words
The compound as claimed in claim 1 wherein the compound is 1-(3,4-dihydroxyphenyl)-3-undecanol.
Claim 6
Dependent Claim
12 words
The compound as claimed in claim 1 wherein the compound is 9-(3,4-dihydroxyphenyl)-2-nonanone.
Claim 7
Dependent Claim
12 words
The compound as claimed in claim 1 wherein the compound is 1-(3,4-dihydroxyphenyl)-4-methyl-3-octanol.
Claim 8
Dependent Claim
32 words
A pharmaceutical composition for inhibiting the production and release of slow reacting substance of anaphylaxis (SRS-A) comprising a pharmaceutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.
Claim 9
Dependent Claim
32 words
A pharmaceutical composition for inhibiting the production and release of slow reacting substance of anaphylaxis (SRS-A) comprising a pharmaceutically effective amount of the compound of claim 2 and a pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
32 words
A pharmaceutical composition for inhibiting the production and release of slow reacting substance of anaphylaxis (SRS-A) comprising a pharmaceutically effective amount of the compound of claim 3 and a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim
32 words
A pharmaceutical composition for inhibiting the production and release of slow reacting substance of anaphylaxis (SRS-A) comprising a pharmaceutically effective amount of the compound of claim 4 and a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
32 words
A pharmaceutical composition for inhibiting the production and release of slow reacting substance of anaphylaxis (SRS-A) comprising a pharmaceutically effective amount of the compound of claim 5 and a pharmaceutically acceptable carrier.
Claim 13
Dependent Claim
32 words
A pharmaceutical composition for inhibiting the production and release of slow reacting substance of anaphylaxis (SRS-A) comprising a pharmaceutically effective amount of the compound of claim 6 and a pharmaceutically acceptable carrier.
Claim 14
Dependent Claim
20 words
The composition of claim 7 wherein said pharmaceutically effective amount is in the range of about 0.03 to 250 mg.
Claim 15
Dependent Claim
38 words
A method of preventing and/or treating disorders of various allergic diseases, ischemic heat diseases or inflamations, caused by slow reacting substance of anaphylaxis (SRS-A) or leukotriens comprising administering a pharmaceutically effective amount of the composition of claim 7.
Claim 16
Dependent Claim
33 words
A method of preventing and/or treating disorders of various allergic diseases, ischemic heat diseases or inflamations, caused by SRS-A or leukotriens comprising administering a pharmaceutically effective amount of the composition of claim 8.
Claim 17
Dependent Claim
33 words
A method of preventing and/or treating disorders of various allergic diseases, ischemic heat diseases or inflamations, caused by SRS-A or leukotriens comprising administering a pharmaceutically effective amount of the composition of claim 9.
Claim 18
Dependent Claim
33 words
A method of preventing and/or treating disorders of various allergic diseases, ischemic heat diseases or inflamations, caused by SRS-A or leukotriens comprising administering a pharmaceutically effective amount of the composition of claim 10.
Claim 19
Dependent Claim
28 words
A method of preventing and/or treating disorders of various allergic diseases, ischemic heat diseases or inflamations, caused by SRS-A or leukotriens comprising administering the composition of claim 11.
Claim 20
Dependent Claim
28 words
A method of preventing and/or treating disorders of various allergic diseases, ischemic heat diseases or inflamations, caused by SRS-A or leukotriens comprising administering the composition of claim 12.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-10-20 | 1990-04-21 | 1990-10-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-10-20 | 1994-04-21 | 1994-10-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-10-20 | 1998-04-21 | 1998-10-21 | $7700.00 | Window Closed / Lapsed |